

CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Currently Amended) A method of blocking an immune response to an allogeneic ~~foreign~~ graft in a mammal, where the mammal is not suffering from a malignancy, comprising administering to the mammal a therapeutically effective amount of an antibody which binds to CD20.
- 2-4. (Cancelled)
5. (Original) The method of claim 1 wherein the mammal is human.
6. (Previously Presented) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.
7. (Previously Presented) The method of claim 1 wherein the antibody comprises rituximab.
8. (Previously Presented) The method of claim 1 wherein the antibody is conjugated with a cytotoxic agent.
9. (Original) The method of claim 8 wherein the cytotoxic agent is a radioactive compound.
10. (Previously Presented) The method of claim 9 wherein the antibody comprises Y2B8 or ¹³¹I-B1.
11. (Previously Presented) The method of claim 1 comprising administering the antibody intravenously.

12. (Previously Presented) The method of claim 1 comprising administering the antibody subcutaneously.
13. (Currently Amended) The method of claim 1, comprising administering a dose of from about 20mg/m² to about 1000 ~~less than 375~~ mg/m² of the antibody to the mammal.
14. (Original) The method of claim 13 wherein the dose is in the range from about 20mg/m² to about 250mg/m².
15. (Original) The method of claim 14 wherein the dose is in the range from about 50mg/m² to about 200mg/m².
16. (Previously Presented) The method of claim 1 comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m² dose of the antibody in the subsequent dose exceeds the mg/m² dose of the antibody in the initial dose.
- 17-21. (Cancelled)
22. (Previously Presented) The method of claim 1 comprising administering the antibody to the mammal before the mammal is exposed to the graft.
- 23-27. (Cancelled)
28. (Currently Amended) A method of treating graft-versus-host or host-versus-graft disease in a ~~mammal~~ human, wherein the graft is from a human having the same or a different genetic origin as the human being treated, comprising administering to the ~~mammal~~ human a therapeutically effective amount of an antibody which binds to CD20.

29-31. (Cancelled)

- 32. (Newly Added) The method of claim 10, wherein the antibody comprises Y2B8.
- 33. (Newly Added) The method of claim 10, wherein the antibody comprises ¹³¹I-B1.
- 34. (Newly Added) The method of claim 1, wherein the antibody is a human antibody.
- 35. (Newly Added) The method of claim 1, wherein the antibody is a chimeric antibody.
- 36. (Newly Added) The method of claim 1, wherein the antibody is a humanized antibody.
- 37. (Newly Added) The method of claim 28, wherein the antibody is a human antibody.
- 38. (Newly Added) The method of claim 28, wherein the antibody is a chimeric antibody.
- 39. (Newly Added) The method of claim 28, wherein the antibody is a humanized antibody.
- 40. (Newly Added) The method of claim 28, wherein the antibody comprises rituximab.
- 41. (Newly Added) The method of claim 28, wherein the antibody comprises Y2B8.
- 42. (Newly Added) The method of claim 28, wherein the antibody comprises ¹³¹I-B1.